-
-
Signals of Change: Recognising the early signs of progression to SPMS
-
Posted in Sponsored Feature
-
26th Nov 2020
-
This report explores four diverse perspectives from across the multidisciplinary team and a person with MS and discusses the landscape and challenges in SPMS diagnosis within the clinical and community setting
-
-
Latest Articles
-
Posted in Clinical Review Article,Contents
-
16th Jul 2020
-
Latest clinical and research articles
-
-
Pregnancy in multiple sclerosis: influence on disease trajectory
-
Posted in Clinical Review Article
-
08th Jul 2020
-
Ruth Dobson and Charmaine Yam
-
-
Raising the bar through leadership: MS Leaders Academy
-
Posted in Courses & Conferences
-
19th Mar 2020
-
An update on the MS Leaders Academy
-
-
Data from Phase III Trial “SPI2” for Treatment of Progressive MS
-
Posted in Industry News
-
11th Mar 2020
-
News from MedDay Pharma
-
-
EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
-
Posted in Industry News
-
21st Jan 2020
-
News from Novartis on the EU approval of Mayzent (siponimod) for adult patients with SPMS with active disease
-
-
Ocrelizumab (Ocrevus®) accepted for use in PPMS within NHS Scotland
-
Posted in Industry News
-
14th Jan 2020
-
Industry news from Roche
-
-
Creating clinical leaders, transformation pioneers and innovation specialists: because change starts from the ground up
-
Posted in Industry News
-
10th Dec 2019
-
Those of us in the room have the power we need to fundamentally improve the quality of multiple sclerosis (MS) care in the UK, reduce variation and offer consistent care at the level we want everywhere, in the next 3 years. In July, 85% of 120 healthcare professionals agreed with this statement (‘Raising the Bar’, […]
-
-
Multiple Sclerosis Patients in the UK to Receive Accelerated Access to MAVENCLAD® (Cladribine Tablets) Following Fast Tracked NICE Guidance Update
-
Posted in Industry News
-
05th Dec 2019
-
Industry news: patients with highly active MS will now have access to cladribine tablets without the additional requirement of a gadolinium-enhanced MRI, following review from NICE.
-
-
EMA approves interferon beta treatments, including Rebif (interferon beta-1a), for relapsing MS patients during pregnancy and breastfeeding
-
Posted in Industry News
-
22nd Oct 2019
-
News from Merck